CN103635460B - 用于治疗成瘾性的化合物 - Google Patents
用于治疗成瘾性的化合物 Download PDFInfo
- Publication number
- CN103635460B CN103635460B CN201280032944.6A CN201280032944A CN103635460B CN 103635460 B CN103635460 B CN 103635460B CN 201280032944 A CN201280032944 A CN 201280032944A CN 103635460 B CN103635460 B CN 103635460B
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- hydrogen
- oxo
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1cccc(Cl)c1C(NCc(cc1)ccc1C(C=CN1)=CC1=O)=* Chemical compound *c1cccc(Cl)c1C(NCc(cc1)ccc1C(C=CN1)=CC1=O)=* 0.000 description 1
- MROYYAOBHCNTQW-UHFFFAOYSA-N O=C(c(c(Cl)ccc1)c1Cl)NCc(cc1)ccc1C(C=CN1)=CC1=O Chemical compound O=C(c(c(Cl)ccc1)c1Cl)NCc(cc1)ccc1C(C=CN1)=CC1=O MROYYAOBHCNTQW-UHFFFAOYSA-N 0.000 description 1
- SPADNYVJQZNTKZ-UHFFFAOYSA-N OP(O)(OCN(C=CC(c1ccc(CNC(c(c(Cl)ccc2)c2Cl)=O)cc1)=C1)C1=O)=O Chemical compound OP(O)(OCN(C=CC(c1ccc(CNC(c(c(Cl)ccc2)c2Cl)=O)cc1)=C1)C1=O)=O SPADNYVJQZNTKZ-UHFFFAOYSA-N 0.000 description 1
- MDFFGYUEWVIAAV-UHFFFAOYSA-N [O-]=C(c(c(Cl)ccc1)c1F)NCc(cc1)ccc1C(C=CN1)=CC1=O Chemical compound [O-]=C(c(c(Cl)ccc1)c1F)NCc(cc1)ccc1C(C=CN1)=CC1=O MDFFGYUEWVIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503923P | 2011-07-01 | 2011-07-01 | |
| US61/503,923 | 2011-07-01 | ||
| PCT/US2012/044809 WO2013006400A1 (en) | 2011-07-01 | 2012-06-29 | Compounds for the treatment of addiction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103635460A CN103635460A (zh) | 2014-03-12 |
| CN103635460B true CN103635460B (zh) | 2016-03-16 |
Family
ID=46513858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280032944.6A Expired - Fee Related CN103635460B (zh) | 2011-07-01 | 2012-06-29 | 用于治疗成瘾性的化合物 |
Country Status (32)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012149106A1 (en) | 2011-04-29 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| ES2648820T3 (es) | 2011-05-10 | 2018-01-08 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de los canales de sodio |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| KR20150135332A (ko) | 2013-03-14 | 2015-12-02 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법 |
| JP6463580B2 (ja) * | 2013-12-13 | 2019-02-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ |
| US10077669B2 (en) | 2014-11-26 | 2018-09-18 | United Technologies Corporation | Non-metallic engine case inlet compression seal for a gas turbine engine |
| US10289971B2 (en) | 2015-02-13 | 2019-05-14 | Atlassian Pty Ltd | Issue and trigger rebalancing in a ranked issue management system |
| HRP20221497T1 (hr) * | 2016-08-19 | 2023-02-17 | The University Of Bristol | Derivati citizina za liječenje ovisnosti |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2019079209A1 (en) * | 2017-10-16 | 2019-04-25 | Amygdala Neurosciences, Inc. | POLYTHERAPY FOR THE PREVENTION OF AN ADDICTION |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US10703733B2 (en) | 2018-05-14 | 2020-07-07 | Gilead Sciences, Inc. | MCL-1 inhibitors |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| WO2020023792A1 (en) * | 2018-07-27 | 2020-01-30 | Amygdala Neurosciences, Inc. | Combination therapy for nicotine addiction |
| WO2020076974A1 (en) * | 2018-10-12 | 2020-04-16 | Amygdala Neurosciences, Inc. | Addiction treatment of an alcohol-consuming patient population |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2023244574A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
| CA3259203A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | ALDH-2 INHIBITING COMPOUNDS AND METHODS OF USE |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010062308A1 (en) * | 2008-10-28 | 2010-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase and methods of use thereof |
| WO2012003189A1 (en) * | 2010-06-29 | 2012-01-05 | Irm Llc | Compositions and methods for modulating the wnt signaling pathway |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5204369A (en) | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| US6121010A (en) | 1998-05-12 | 2000-09-19 | The Endowment For Research In Human Biology | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| KR20060011785A (ko) * | 2002-06-27 | 2006-02-03 | 디 인다우먼트 포 리써치 인 휴먼 바이올로지, 인크. | Ａｌｄｈ 억제에 유용한 화합물 |
| JP2004182657A (ja) * | 2002-12-04 | 2004-07-02 | Eisai Co Ltd | Ｈｄｌレベル上昇促進剤 |
| US20080004260A1 (en) | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
| US8158810B2 (en) | 2006-07-27 | 2012-04-17 | Gilead Sciences, Inc. | ALDH-2 inhibitors in the treatment of addiction |
| US20080207610A1 (en) | 2006-07-27 | 2008-08-28 | Jeff Zablocki | Aldh-2 inhibitors in the treatment of addiction |
| EP2046769A2 (en) * | 2006-07-27 | 2009-04-15 | Cv Therapeutics, Inc. | Aldh-2 inhibitors in the treatment of addiction |
| EP2126574B1 (en) | 2007-03-08 | 2015-12-23 | The Board of Trustees of the Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| MX2010008111A (es) | 2008-01-24 | 2010-11-30 | Endowment For Res In Human Biology Inc | Inhibidores de aldh-2 en el tratamiento de adicciones. |
| NZ588954A (en) | 2008-05-01 | 2012-08-31 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2010028175A1 (en) | 2008-09-08 | 2010-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
-
2012
- 2012-06-26 TW TW101122794A patent/TWI567061B/zh not_active IP Right Cessation
- 2012-06-27 UY UY0001034165A patent/UY34165A/es not_active Application Discontinuation
- 2012-06-28 AR ARP120102331A patent/AR086792A1/es not_active Application Discontinuation
- 2012-06-29 MD MDA20140009A patent/MD4436B1/ro not_active IP Right Cessation
- 2012-06-29 CA CA2840763A patent/CA2840763C/en active Active
- 2012-06-29 EA EA201391635A patent/EA025573B1/ru not_active IP Right Cessation
- 2012-06-29 KR KR1020147002302A patent/KR101664915B1/ko not_active Expired - Fee Related
- 2012-06-29 US US13/537,536 patent/US8558001B2/en active Active
- 2012-06-29 ES ES12735394.4T patent/ES2553829T3/es active Active
- 2012-06-29 ES ES15184883.5T patent/ES2656716T3/es active Active
- 2012-06-29 JP JP2014519122A patent/JP5943998B2/ja not_active Expired - Fee Related
- 2012-06-29 CN CN201280032944.6A patent/CN103635460B/zh not_active Expired - Fee Related
- 2012-06-29 PE PE2013002811A patent/PE20141067A1/es not_active Application Discontinuation
- 2012-06-29 BR BR112014000033A patent/BR112014000033A2/pt active Search and Examination
- 2012-06-29 KR KR1020167023967A patent/KR20160106207A/ko not_active Withdrawn
- 2012-06-29 PL PL12735394T patent/PL2726460T3/pl unknown
- 2012-06-29 PH PH1/2013/502674A patent/PH12013502674A1/en unknown
- 2012-06-29 MX MX2013014938A patent/MX337611B/es active IP Right Grant
- 2012-06-29 SI SI201230340T patent/SI2726460T1/sl unknown
- 2012-06-29 WO PCT/US2012/044809 patent/WO2013006400A1/en not_active Ceased
- 2012-06-29 EP EP15184883.5A patent/EP2993170B1/en active Active
- 2012-06-29 PT PT127353944T patent/PT2726460E/pt unknown
- 2012-06-29 UA UAA201314148A patent/UA109199C2/ru unknown
- 2012-06-29 SG SG10201605355RA patent/SG10201605355RA/en unknown
- 2012-06-29 AP AP2013007282A patent/AP3544A/xx active
- 2012-06-29 AU AU2012279332A patent/AU2012279332B2/en not_active Ceased
- 2012-06-29 EP EP12735394.4A patent/EP2726460B1/en active Active
- 2012-06-29 DK DK15184883.5T patent/DK2993170T3/da active
-
2013
- 2013-03-08 US US13/791,422 patent/US8575353B2/en active Active
- 2013-08-13 US US13/966,029 patent/US9000015B2/en active Active
- 2013-11-28 ZA ZA2013/08977A patent/ZA201308977B/en unknown
- 2013-12-13 CR CR20130659A patent/CR20130659A/es unknown
- 2013-12-16 CL CL2013003597A patent/CL2013003597A1/es unknown
- 2013-12-18 CO CO13295408A patent/CO6821964A2/es active IP Right Grant
- 2013-12-18 EC ECSP13013087 patent/ECSP13013087A/es unknown
- 2013-12-30 MA MA36629A patent/MA35404B1/fr unknown
-
2014
- 2014-01-26 IL IL230657A patent/IL230657B/en active IP Right Grant
-
2015
- 2015-03-16 US US14/659,042 patent/US9610299B2/en not_active Expired - Fee Related
-
2017
- 2017-03-31 US US15/476,569 patent/US9987295B2/en active Active
-
2018
- 2018-05-08 US US15/974,171 patent/US10507215B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010062308A1 (en) * | 2008-10-28 | 2010-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase and methods of use thereof |
| WO2012003189A1 (en) * | 2010-06-29 | 2012-01-05 | Irm Llc | Compositions and methods for modulating the wnt signaling pathway |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103635460B (zh) | 用于治疗成瘾性的化合物 | |
| US7951813B2 (en) | Quinazolinone derivatives as ALDH-2 inhibitors | |
| TWI468403B (zh) | 用於治療成癮之ａｌｄｈ－２抑制劑 | |
| JP2020536970A (ja) | 嗜癖を予防するための組み合わせ療法 | |
| EP4605084A2 (en) | 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- d]pyrimidin-4-ones for wound treatment | |
| HK1217487B (en) | N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide derivatives as aldh-2 inhibitors for the treatment of addiction | |
| AU2015202264A1 (en) | Compounds for the treatment of addiction | |
| NZ618537B2 (en) | Mitochondrial aldehyde dehydrogenase (ALDH-2) inhibitors | |
| OA16801A (en) | Compounds for the treatment of addiction. | |
| AU2016244324A1 (en) | Compounds for the treatment of addiction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191204 Address after: California, USA Patentee after: Amygdala neuroscience Co. Address before: California, USA Patentee before: GILEAD SCIENCES, Inc. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160316 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |